iBio, Inc. IBIO

IBIO Company Overview

iBio, Inc. is a U.S.-based biotechnology company focused on the discovery and development of therapeutic antibodies and precision biologics. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on obesity, cardiometabolic disease, and immunology-related therapeutic development. Historically, iBio was known for its plant-based biologics manufacturing platform and contract development capabilities, but the company has evolved into a drug discovery and antibody engineering organization centered on artificial intelligence-enabled biologic discovery technologies.

The company’s primary business activities include antibody discovery, preclinical biologic development, and the advancement of internally owned therapeutic candidates. iBio has positioned itself around computational biology and epitope steering technologies intended to accelerate antibody identification and optimization. Its transition away from large-scale contract manufacturing toward proprietary therapeutic pipelines reflects a broader strategic shift undertaken after the COVID-19 pandemic period, when interest in plant-based vaccine production temporarily increased the company’s visibility. The company primarily serves biotechnology investors, research collaborators, and potentially future pharmaceutical partners seeking novel biologic assets.